A share price of Black Diamond Therapeutics Inc [BDTX] is currently trading at $2.5, down -3.10%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BDTX shares have gain 6.38% over the last week, with a monthly amount drifted -1.57%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Raymond James started tracking the stock with Outperform rating on July 31, 2024, and set its price target to $20. On July 14, 2023, Piper Sandler initiated with a Overweight rating. Stifel upgraded its rating to a Buy and increased its price target to $10 on June 30, 2023. H.C. Wainwright upgraded its rating to a Buy but $11 remained the price target by the analyst firm on June 28, 2023. Wedbush upgraded its rating to Outperform for this stock on June 27, 2023, but kept the price target unchanged to $10. In a note dated March 29, 2022, Wedbush downgraded an Neutral rating on this stock.
Black Diamond Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $1.20 and $6.75. Currently, Wall Street analysts expect the stock to reach $14.75 within the next 12 months. Black Diamond Therapeutics Inc [NASDAQ: BDTX] shares were valued at $2.5 at the most recent close of the market. An investor can expect a potential return of 490.0% based on the average BDTX price forecast.
Analyzing the BDTX fundamentals
Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -0.06%, Pretax Profit Margin comes in at 0.07%, and Net Profit Margin reading is 0.07%. To continue investigating profitability, this company’s Return on Assets is posted at 0.03, Equity is 0.05 and Total Capital is -0.03. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.44 points at the first support level, and at 2.38 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.55, and for the 2nd resistance point, it is at 2.61.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Black Diamond Therapeutics Inc [NASDAQ:BDTX] is 9.24. Further, the Quick Ratio stands at 9.24, while the Cash Ratio is 5.84. Considering the valuation of this stock, the price to sales ratio is 2.03, the price to book ratio is 1.00 and price to earnings (TTM) ratio is 40.52.
Transactions by insiders
Recent insider trading involved BIOTECH GROWTH N V, 10% Owner, that happened on Mar 19 ’25 when 5.78 million shares were sold. 10% Owner, Versant Venture Capital VI, L. completed a deal on Aug 28 ’24 to sell 0.22 million shares. Meanwhile, Former Employer David Epstein bought 50000.0 shares on Jul 31 ’24.
